Is Bionano Genomics, Inc. (BNGO) Halal?

NASDAQ Healthcare United States $13M
✗ NOT HALAL
Confidence: 90/100
Bionano Genomics, Inc. (BNGO) is Not Halal under AAOIFI Standard 21. The company's debt ratio of 60.8% exceeds the 30% threshold, indicating excessive interest-bearing debt relative to market capitalization. Bionano Genomics, Inc. operates in the Healthcare sector.

Shariah Screening — 5 Standards

Based on financial data from December 2024

Standard Debt Ratio Cash Ratio Receivables Income Status
AAOIFI 60.8%
/ 30%
83.1%
/ 30%
41.9%
/ 30%
6.83%
/ 5%
✗ NOT HALAL
DJIM 60.8%
/ 33%
83.1%
/ 33%
41.9%
/ 33%
6.83%
/ 5%
✗ NOT HALAL
MSCI 9.0%
/ 33%
12.4%
/ 33%
6.2%
/ 33%
6.83%
/ 5%
✗ NOT HALAL
S&P 60.8%
/ 33%
83.1%
/ 33%
41.9%
/ 33%
6.83%
/ 5%
✗ NOT HALAL
FTSE 9.0%
/ 33%
12.4%
/ 33%
6.2%
/ 50%
6.83%
/ 5%
✗ NOT HALAL

Financial Highlights

EPS
$-4.85
P/B Ratio
0.3
EV/EBITDA
-0.4
EV: $10M
Revenue
$31M
Growth: -2.6%
Beta
1.7
High volatility
Current Ratio
2.0

Profitability

Gross Margin 46.2%
Operating Margin -107.4%
Net Margin -92.6%
Return on Equity (ROE) -66.2%
Return on Assets (ROA) -27.7%

Cash Flow & Balance Sheet

Operating Cash Flow-$69M
Free Cash Flow-$69M
Total Debt$7M
Debt-to-Equity38.0
Current Ratio2.0
Total Assets$77M

Price & Trading

Last Close$1.15
50-Day MA$1.23
200-Day MA$2.17
Avg Volume188K
Beta1.7
52-Week Range
$1.06
$5.50

About Bionano Genomics, Inc. (BNGO)

CEO
Dr. Robert Erik Holmlin M.B.A., Ph.D.
Sector
Healthcare
Industry
Medical Instruments & Supplies
Country
United States
Exchange
NASDAQ
Market Cap
$13M
Currency
USD

Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It also provides Saphyr and Stratys systems, which are sample-to-result solutions for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr and Stratys instruments, which are single-molecule imagers; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA; and Ionic purification system, which isolates and purifies nucleic acid molecules. In addition, the company offers Saphyr, Stratys, and Bionano compute servers; and VIA software, which offers one solution for analysis and interpretation of genomic data from microarray and sequencing data for cytogenetics and molecular genetics. Further, it provides testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.

Related Halal Stocks in Healthcare

Frequently Asked Questions

Is Bionano Genomics, Inc. (BNGO) halal to invest in?

Based on our screening using AAOIFI Standard 21 (the strictest methodology), Bionano Genomics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.

What is Bionano Genomics, Inc.'s debt ratio?

Bionano Genomics, Inc.'s debt ratio is 60.8% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 9.0%.

What are Bionano Genomics, Inc.'s key financial metrics?

Bionano Genomics, Inc. has a market capitalization of $13M, and revenue of $31M. The company maintains a gross margin of 46.2% and a net margin of -92.6%. Return on equity stands at -66.2%.

How often is the screening data updated?

Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.